The Hong Kong headquartered company says its idiopathic pulmonary fibrosis drug performed well in a phase 2a trial and met ...

The series A financing will enable Nura Bio to advance its lead drug candidate into the next stage of clinical trials, ...

The German big pharma will submit a new drug application to the US FDA after success at phase 3 for nerandomilast.

Alison has more than 35 years of broad experience delivering clinical trials to sponsors with a patient centric mindset.

One year after a rejection by the US Food and Drug Administration (FDA), the UK firm F2G has raised $100 million to push its candidate olorofim to the market for the treatment of rare fungal ...

Motif, a fast-growing company in the clinical research technology sector, has taken a significant step in expanding its ...

Rachel Sha has had a colorful career not without its challenges, but she urges women in the science industry to have ...

Applying AI-enabled route scouting services allows drug developers to avoid pitfalls that can typically occur in drug ...